{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:40:07Z","timestamp":1758552007320,"version":"3.44.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Supported by Fujian Provincial Natural Science Foundation of China","award":["[2024J01586]"],"award-info":[{"award-number":["[2024J01586]"]}]},{"name":"Joint Funds for the innovation of Science and Technology","award":["[2023Y9161]"],"award-info":[{"award-number":["[2023Y9161]"]}]},{"name":"Fujian Provincial Medical 'Dual High' Construction Fund Support","award":["(MWB Health [2021] No. 76)"],"award-info":[{"award-number":["(MWB Health [2021] No. 76)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1245\/s10434-025-17738-3","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T10:51:09Z","timestamp":1751539869000},"page":"7999-8012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping: Chemotherapy, Immunotherapy, or Targeted Therapy?\u2014A Retrospective Analysis"],"prefix":"10.1245","volume":"32","author":[{"given":"Hua-Long","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Li","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao-Ling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Xian","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-Deng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8680-3127","authenticated-orcid":false,"given":"Chao-Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"17738_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"17738_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"C David","year":"2006","unstructured":"David C, William HA, Sally PS, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11\u201320.","journal-title":"N Engl J Med."},{"issue":"13","key":"17738_CR3","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1200\/JCO.2010.33.0597","volume":"29","author":"M Ychou","year":"2011","unstructured":"Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715\u201321.","journal-title":"J Clin Oncol."},{"issue":"14","key":"17738_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev-pathmechdis-012418-012751","volume":"24","author":"W Gu","year":"2019","unstructured":"Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection. Annu Rev Pathol. 2019;24(14):319\u201338.","journal-title":"Annu Rev Pathol."},{"issue":"9","key":"17738_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.tig.2014.07.001","volume":"30","author":"EL Dijk","year":"2014","unstructured":"Dijk EL, Auger H, Jaszczyszyn Y, et al. Ten years of next-generation sequencing technology. Trends Genet. 2014;30(9):418\u201326.","journal-title":"Trends Genet."},{"key":"17738_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.semcancer.2022.12.009","volume":"88","author":"X He","year":"2023","unstructured":"He X, Liu X, Zuo F, et al. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Semin Cancer Biol. 2023;88:187\u2013200.","journal-title":"Semin Cancer Biol."},{"key":"17738_CR7","first-page":"513","volume":"11","author":"Cancer Genome Atlas Research","year":"2014","unstructured":"Cancer Genome Atlas Research. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;11:513.","journal-title":"Nature."},{"issue":"5","key":"17738_CR8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449\u201356.","journal-title":"Nat Med."},{"issue":"3","key":"17738_CR9","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1053\/j.gastro.2013.05.010","volume":"145","author":"Z Lei","year":"2013","unstructured":"Lei Z, Tan IB, Das K, Deng N, Zouridis H, Pattison S, Chua C, Feng Z, Guan YK, Ooi CH, Ivanova T. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology. 2013;145(3):554\u201365.","journal-title":"Gastroenterology"},{"key":"17738_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449\u201356.","journal-title":"Nat Med"},{"key":"17738_CR11","unstructured":"Lei, Z. On the subtyping of gastric cancer in the 16th Chinese Gastric Cancer Congress (Shanghai, 2021)."},{"issue":"2","key":"17738_CR12","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a004945","volume":"6","author":"M Sorokin","year":"2020","unstructured":"Sorokin M, et al. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud. 2020;6(2):a004945.","journal-title":"Cold Spring Harb Mol Case Stud."},{"issue":"7","key":"17738_CR13","first-page":"747","volume":"78","author":"J Lesley","year":"2018","unstructured":"Lesley J. Scott Apatinib a review in advanced gastric cancer and other. Adv Cancer Drugs. 2018;78(7):747\u201358.","journal-title":"Adv Cancer Drugs."},{"issue":"13","key":"17738_CR14","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","volume":"34","author":"J Li","year":"2016","unstructured":"Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. 2016;34(13):1448\u201354.","journal-title":"J Clin Oncol."},{"issue":"3","key":"17738_CR15","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10120-018-0813-2","volume":"21","author":"TT Zhao","year":"2018","unstructured":"Zhao TT, Xu H, Xu HM, et al. The efficacy and safety of targeted therapy with or without chemotherapy in advanced gastric cancer treatment: a network meta-analysis of well-designed randomized controlled trials. Gastric Cancer. 2018;21(3):361\u201371.","journal-title":"Gastric Cancer."},{"issue":"8","key":"17738_CR16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/cac2.12193","volume":"41","author":"FH Wang","year":"2021","unstructured":"Wang FH, Zhang XT, Li YF, et al. The chinese society of clinical oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond). 2021;41(8):747\u201395.","journal-title":"Cancer Commun (Lond)."},{"issue":"7","key":"17738_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.16240","volume":"4","author":"JX Lin","year":"2021","unstructured":"Lin JX, Xu YC, Lin W, et al. Effectiveness and safety of apatinib plus chemotherapy as neoadjuvant treatment for locally advanced gastric cancer a nonrandomized controlled trial. JAMA Netw Open. 2021;4(7):e2116240.","journal-title":"JAMA Netw Open."},{"issue":"1","key":"17738_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41467-023-44309-5","volume":"15","author":"JX Lin","year":"2024","unstructured":"Lin JX, Tang YH, Zheng HL, et al. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial. Nat Commun. 2024;15(1):41.","journal-title":"Nat Commun."},{"key":"17738_CR19","volume-title":"TNM classification of malignant tumors","author":"LH Sobin","year":"2010","unstructured":"Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors. 7th edn. Oxford: Wiley-Blackwell; 2010.","edition":"7"},{"issue":"20","key":"17738_CR20","first-page":"1","volume":"2017","author":"Japanese gastric cancer treatment guidelines","year":"2014","unstructured":"Japanese gastric cancer treatment guidelines. Japanese gastric cancer treatment guidelines (ver 4). Gastric Cancer. 2014;2017(20):1\u201319.","journal-title":"Gastric Cancer"},{"issue":"2","key":"17738_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: revised RECIST guideline. Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"7","key":"17738_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","volume":"98","author":"K Becker","year":"2003","unstructured":"Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521\u201330.","journal-title":"Cancer"},{"issue":"2","key":"17738_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA, et al. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205\u201313.","journal-title":"Ann Surg."},{"issue":"6","key":"17738_CR24","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/bjs.10486","volume":"104","author":"LAD Busweiler","year":"2017","unstructured":"Busweiler LAD, Schouwenburg MG, Henegouwen MIB, et al. Textbook outcome as a composite measure in esophagogastric cancer surgery. Br J Surg. 2017;104(6):742\u201350.","journal-title":"Br J Surg."},{"issue":"12","key":"17738_CR25","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1245\/s10434-017-6078-x","volume":"24","author":"I Haejin","year":"2017","unstructured":"Haejin I, Solsky I, Palis B, et al. Validation of the 8th edition of the AJCC TNM Staging System for Gastric cancer using the National cancer Database. Ann Surg Oncol. 2017;24(12):3683.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"17738_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s10120-011-0043-3","volume":"14","author":"T Hara","year":"2011","unstructured":"Hara T, Nishikawa K, Sakatoku M, et al. Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer. Gastric Cancer. 2011;14(4):332\u20138.","journal-title":"Gastric Cancer."},{"key":"17738_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijsu.2018.01.008","volume":"51","author":"F Coccolini","year":"2018","unstructured":"Coccolini F, Nardi M, Montori G, et al. Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. Int J Surg. 2018;51:120\u20137.","journal-title":"Int J Surg."},{"issue":"70","key":"17738_CR28","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1146\/annurev-med-081117-043436","volume":"27","author":"AE Russo","year":"2019","unstructured":"Russo AE, Strong VE. Gastric cancer etiology and management in Asia and the West. Annu Rev Med. 2019;27(70):353\u201367.","journal-title":"Annu Rev Med."},{"issue":"9","key":"17738_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11864-020-00774-4","volume":"21","author":"TH Patel","year":"2020","unstructured":"Patel TH, Cecchini M. Targeted therapies in advanced gastric cancer. Curr Treat Options Oncol. 2020;21(9):70.","journal-title":"Curr Treat Options Oncol."},{"issue":"5","key":"17738_CR30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","volume":"23","author":"DJ Hicklin","year":"2005","unstructured":"Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011\u201327.","journal-title":"J Clin Oncol."},{"key":"17738_CR31","doi-asserted-by":"crossref","unstructured":"L Cao, H Lu, M Soutto et al. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumor-intrinsic IFN-\u03b3 signaling. Gut. 2023; gutjnl-2022-329134.","DOI":"10.1136\/gutjnl-2022-329134"},{"issue":"3","key":"17738_CR32","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1053\/j.gastro.2013.07.019","volume":"145","author":"ES Turner","year":"2013","unstructured":"Turner ES, Turner JR. Expanding the Lauren classification: a new gastric cancer subtype? Gastroenterology. 2013;145(3):505\u20138.","journal-title":"Gastroenterology."},{"issue":"5","key":"17738_CR33","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","volume":"253","author":"K Becker","year":"2011","unstructured":"Becker K, Langer R, Reim D, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253(5):934\u20139.","journal-title":"Ann Surg."},{"issue":"5","key":"17738_CR34","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/SLA.0b013e3182a66588","volume":"258","author":"CL Donohoe","year":"2013","unstructured":"Donohoe CL, O\u2019Farrell NJ, Grant T, et al. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: assessment of existing measures and proposal of a novel 3-point standard. Ann Surg. 2013;258(5):784\u201392.","journal-title":"Ann Surg."},{"issue":"10294","key":"17738_CR35","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Wei J, Wang F, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet."},{"issue":"2","key":"17738_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324.","journal-title":"Lancet Oncol."},{"issue":"2","key":"17738_CR37","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.surg.2022.03.005","volume":"172","author":"P Prasad","year":"2022","unstructured":"Prasad P, Sivaharan A, Navidi M, et al. Significance of neoadjuvant downstaging in gastric adenocarcinoma. Surgery. 2022;172(2):593\u2013601.","journal-title":"Surgery."},{"issue":"30","key":"17738_CR38","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","volume":"29","author":"A Ohtsu","year":"2011","unstructured":"Ohtsu A, Shah MA, Van CE, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29(30):3968\u201376.","journal-title":"J Clin Oncol."},{"key":"17738_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31\u20139.","journal-title":"Lancet."},{"issue":"1","key":"17738_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41467-022-35431-x","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Yu W, Xie F, et al. Neoadjuvant therapy with immune checkpoint blockade, anti-angiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023;14(1):8.","journal-title":"Nat Commun."},{"issue":"11","key":"17738_CR41","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1158\/1078-0432.CCR-20-4691","volume":"27","author":"Z Peng","year":"2021","unstructured":"Peng Z, Wei J, Wang F, et al. Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res. 2021;27(11):3069.","journal-title":"Clin Cancer Res."},{"issue":"4","key":"17738_CR42","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","volume":"72","author":"R Seiler","year":"2017","unstructured":"Seiler R, Ashab HAD, Erho N, et al. Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72(4):544\u201354.","journal-title":"Eur Urol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17738-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T14:05:30Z","timestamp":1758549930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17738-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["17738"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17738-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"type":"print","value":"1068-9265"},{"type":"electronic","value":"1534-4681"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Written informed consent was obtained from all participants (or their legal guardians) for publication of the data and any accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"This study was approved by the Institutional Review Boards of Fujian Medical University Union Hospital (2022KY123). This study was registered on ClinicalTrials.gov (registration no. NCT06376773). This study did not interfere with the treatment intentions of the patients, and an application for exemption from informed consent has been submitted. The Ethics Committee of Fujian Medical University Union Hospital waived the requirement for informed consent owing to the anonymized nature of the retrospective data. All procedures conducted adhered to the ethical standards set by the responsible committee on human experimentation (institutional and national) and the Helsinki Declaration of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}